García-Montalvo BM, Galguera-Colorado PL

Language: English
References: 29
Page: 345-349
PDF size: 113.58 Kb.

Text Extraction

Aim: To make a preliminary determination of hepatitis C virus (HCV) genotype prevalence and possible genotype associations with risk factors and severity of associated liver disease in patients from Yucatan, Mexico. Methods: Sera from 54 patients with positive anti-HCV and HCV RNA were genotyped using reverse transcription-polymerase chain reaction. Risk factors were evaluated using a questionnaire. The evaluations also included serum ALT levels and liver biopsies in some participants. Results: HCV genotype 1 was detected in 37%, genotype 2 in 33.3%, genotype 3 in 16.7% and mixed genotypes in 7.4%. Subtype 2b was the most frequent (33.3%), followed by 1b (18.5%), 3a (16.7%) and 1a (14.8%). Surgeries (53.7%) and transfusion (38.9%) were the main risk factors. Liver biopsies were available in 24 (44.4%) patients. Severe liver disease was present in 6 (54.5%) of the patients with genotype 1 and in none of those with genotype 2. A statistically significant association was observed between patients with a family history of liver disease and genotype 2 (P = 0.021). Liver damage severity increased with longer duration of infection (P = 0.007). No statistically significant association was observed between severe liver damage and the different genotypes. Conclusion: Subtype 2b was the most prevalent. This contrasts with the studies done in different states of Mexico in that this subtype was not identified or had prevalence approximately 2 times less than reported here.

REFERENCES

1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the viral hepatitis prevention board, antwerp, Belgium. J Viral Hepat 1999; 6: 35-47.

2. Darwish MA, Faris R, Darwish N, Shouman A, Gadallah M, El-Sharkawy MS, Edelman R, et al. Hepatitis C and cirrhotic liver disease in the Nile delta of Egipt: a community-based study. Am J Trop Med Hyg 2001; 64: 147-53.

3. Chlabicz S, Bonifatiuk I, Radziwon P. Prevalence of hepatitis C virus antibodies among blood donors in north-eastern Poland. Hepatol Res 2005; 33: 206-10.

4. Chandra M, Khaja MN, Farees N, Poduri CD, Hussain MM, Aejaz Habeeb M, Habibullah CM. Prevalence, risk factors and genotype distribution of HCV and HBV infection in the tribal population: a community based study in south India. Trop Gastroenterol 2003; 24: 193-5.

5. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-6.

6. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132: 296-305.

7. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000; 13: 223-35.

8. Hissar SS, Goyal A, Kumar M, Pandey C, Suneetha PV, Sood A, Midha V, et al. Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease. J Med Virol 2006; 78: 452-8.

9. Matsumura H, Moriyama M, Goto I, Tanaka N, Okubo H, Arakawa Y. Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C-a study of 527 patients at one establishment. J Viral Hepat 2000; 7: 268-75.

10. Haushofer AC, Kopty C, Hauer R, Brunner H, Halbmayer WM. HCV genotypes and age distribution in patients or Vienna and surrounding areas. J Clin Virol 2001; 20: 41-7.

11. Martinot-Peignoux M, Roudot-Thoraval F, Mendel I, Coste J, Izopet J, Duverlie G, Payan C, et al. The GEMHEP. Hepatitis C genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. J Viral Hepat 1999; 6: 435-43.

12. Hopf U, Berg T, Konig V, Kuther S, Heuf HG, Lobeck H. Treatment of chronic hepatitis C with interferon alpha: long-term follow-up and prognostic relevance of HCV genotypes. J Hepatol 1996; 24: 67-73.

13. Vazquez-Flores JA, Valiente-Banuet L, Marin y Lopez RA, Sanchez-Guerrero SA. Safety of the blood supply in Mexico from 1999 to 2003. Rev Invest Clin 2006; 58: 101-8.

14. Bukh J, Purcell RH, Miller RH. Importance of primer selection for the detection of hepatitis C virus RNA with the polymerase chain reaction assay. Proc Natl Acad Sci USA 1992; 89: 187-91.

15. García-Montalvo BM, Macossay-Castillo M. Preliminary data for genotype distribution and epidemiological aspects of hepatitis C virus infection in blood donors from Yucatan, Mexico. Transfus Med 2007; 17: 488-90.

16. Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, Mukaide M, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997; 35: 201-7.

17. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.

18. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH. Hepatitis C virus genotypes in the United Sates: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 1996; 125: 634-9.

19. Mendez-Sanchez N, Motola-Kuba D, Chavez-Tapia NC, Bahena J, Correa-Rotter R, Uribe M. Prevalence of hepatitis C infection among hemodialysis patients at a tertiary-care hospital in Mexico City, Mexico. J Clin Microbiol 2004; 42: 4321-2.

20. Cital-Zamora JL, Navarrete-Castro R, Magaña-Muñoz KD, Martinez-Rodriguez MA, Calderon GM. Prevalence of hepatitis C virus genotypes in a Mexican population. Arch Med Res 2005; 36: 607.

21. Vera de Leon L, Juarez-Navarro JA, Diaz-Gomez M, Mendez-Navarro J, Chirino-Sprung RA, Dehesa-Violante M, Casillas-Davila L, et al. Epidemiologic and situational panorama of hepatitis C in Mexico. Rev Gastroenterol Mex 2005; 70: 25-32.

22. Bourliere M, Barberin JM, Rotily M, Guagliardo V, Portal I, Lecomte L, Benali S, et al. Epidemiological changes in hepatitis C virus genotypes in France evidence in intravenous drug users. J Viral Hepat 2002; 9: 62-70.

23. Persico M, Perrotta S, Persico E, Terracciano L, Folgori A, Ruggeri L, Nicosia A, et al. Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years. J Viral Hepat 2006; 13: 290-6.

24. Collier JD, Woodall T, Wight DGD, Shore S, Gimson AE, Alexander GJM. Predicting progressive hepatic fibrosis stage on subsequent liver biopsy in chronic hepatitis C virus infection. J Viral Hepat 2005; 12: 74-80.

25. Puoti C, Castellacci R, Montagnese F, Zaltron S, Stornaiuolo G, Bergami N, Bellis L, et al. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). J Hepatol 2002; 37: 117-23.

26. Rider SD, Irving WL, Jones DA, Neal KR, Underwood JC; Trent Hepatitis C Study Group. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004; 53: 451-5.

27. Pozzato G, Kaneko S, Moretti M, Croce LS, Franzin F, Unoura M, Bercich L, et al. Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease. J Med Virol 1994; 43: 291-6.

28. Serra MA, Rodriguez F, del Olmo JA, Escudero A, Rodrigo JM. Influence of age and date of infection on distribution of hepatitis C virus genotypes and fibrosis stage. J Viral Hepat 2003; 10: 183-8.

29. Benvegnu L, Pontisso P, Cavalletto D, Noventa F, Chemello L, Alberti A. Lack of correlation between hepatitis C genotypes and clinical course of hepatitis C virus related cirrhosis. Hepatology 1997; 25: 211-5.